What is C3 (Complement 3) glomerulonephritis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 13, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

C3 glomerulonephritis is a type of kidney disease characterized by the deposition of C3 in the glomerulus, resulting from complement dysregulation.

Key Characteristics

  • It is a form of C3 glomerulopathy, which also includes dense deposit disease (C3DDD) 1
  • It is distinguished from other C-dysregulatory disorders, such as atypical hemolytic uremic syndrome (HUS), which results in endothelial injury alone 1
  • The disease is characterized by the presence of C3 deposits in the glomerulus, with or without C4 deposits 1

Diagnosis

  • Diagnosis is typically made by kidney biopsy, which shows a membranoproliferative pattern of injury and C3 deposits on immunofluorescence microscopy 1
  • It is essential to distinguish C3 glomerulonephritis from other diseases that can present with similar histologic characteristics, such as monoclonal deposition diseases and autoimmune immune complex diseases 1

Association with Monoclonal Gammopathy

  • C3 glomerulonephritis is often associated with monoclonal gammopathy, particularly in patients over 50 years old 1
  • The presence of monoclonal immunoglobulin deposits can be masked in some cases, requiring additional immunofluorescence studies on protease-digested, paraffin-embedded tissue for identification 1

From the Research

Definition and Characteristics of C3 Glomerulonephritis

  • C3 glomerulonephritis (C3GN) is a disorder that typically results from abnormalities in the alternative pathway (AP) of complement 2.
  • It is characterized by the deposition of C3 in the glomerulus, leading to damage to the glomerular filtration unit and presenting with features of the nephritic and nephrotic syndromes 3.
  • C3GN is a part of a group of diseases known as C3 glomerulopathy (C3G), which also includes dense deposit disease (DDD) 4, 5.

Pathogenesis and Causes

  • The pathogenesis of C3GN is attributed to dysregulation of the alternative complement pathway, either due to genetic variants or acquired humoral factors 3, 6.
  • Acquired factors, such as autoantibodies that target the C3 or C5 convertases, drive complement dysregulation in most patients 6.
  • Genetic variation in complement-related genes is a less frequent cause of C3GN 6.

Clinical Features and Diagnosis

  • C3GN typically presents with hematuria and proteinuria, and can affect all ages and both genders 2.
  • Kidney biopsy findings may show a membranoproliferative pattern, mesangial proliferative, or diffuse endocapillary proliferative glomerulonephritis 2.
  • Diagnosis is based on the presence of dominant C3 deposition in the glomeruli by immunofluorescence, as well as electron microscopic features 5.

Treatment and Prognosis

  • Treatment options for C3GN are limited, and the prognosis is often poor 3.
  • Immunosuppressive agents and terminal complement pathway blockers may be helpful in some patients 6.
  • Clinical trials are underway to test the efficacy of several first-generation drugs that target the alternative complement pathway 3, 6.
  • Renal transplantation is associated with a high risk of disease recurrence in allograft recipients 6.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Update on C3 Glomerulopathy.

Advances in kidney disease and health, 2024

Research

Treatment of C3 glomerulopathy with complement blockers.

Seminars in thrombosis and hemostasis, 2014

Research

C3 glomerulopathy and current dilemmas.

Clinical and experimental nephrology, 2017

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.